Joseph Soufer

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, The Lancet.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

J. Rosenstock, R. Heine, S. Kahn, 2021, The Lancet.

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Raymond L. Forbes, A. Astrup, F. Greenway, 2017, The Lancet.

High-Strength Capsaicin Cream 0.25% in a Lidocaine-Containing Vehicle (Axsain™) Is a Safe and Effective Adjunctive Treatment for Painful Diabetic Neuropathy or Postherpetic Neuralgia

Daniel B Rowe, S. Schwartz, S. Phillips, 2005 .

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.